CA2245398E - Clathrate d'isopropanol monohydrate d'azithromycine et methodes d'obtention - Google Patents

Clathrate d'isopropanol monohydrate d'azithromycine et methodes d'obtention

Info

Publication number
CA2245398E
CA2245398E CA2245398A CA2245398A CA2245398E CA 2245398 E CA2245398 E CA 2245398E CA 2245398 A CA2245398 A CA 2245398A CA 2245398 A CA2245398 A CA 2245398A CA 2245398 E CA2245398 E CA 2245398E
Authority
CA
Canada
Prior art keywords
azithromycin
isopropanol
degree
water
monohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2245398A
Other languages
English (en)
Other versions
CA2245398C (fr
CA2245398A1 (fr
Inventor
Khashayar Karimian
Mehrnoush Motamedi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Apotex Inc
Apotex Technologies Inc
Filing date
Publication date
Application filed by Apotex Inc, Apotex Technologies Inc filed Critical Apotex Inc
Priority claimed from CA002245398A external-priority patent/CA2245398C/fr
Priority to CA002245398A priority Critical patent/CA2245398C/fr
Priority to US09/373,549 priority patent/US6245903B1/en
Priority to AT99306612T priority patent/ATE221078T1/de
Priority to EP99306612A priority patent/EP0984020B1/fr
Priority to DE69902212T priority patent/DE69902212T2/de
Publication of CA2245398A1 publication Critical patent/CA2245398A1/fr
Publication of CA2245398E publication Critical patent/CA2245398E/fr
Publication of CA2245398C publication Critical patent/CA2245398C/fr
Application granted granted Critical
Priority to US10/454,586 priority patent/USRE39087E1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

CA002245398A 1998-08-21 1998-08-21 Clathrate d'isopropanol monohydrate d'azithromycine et methodes d'obtention Expired - Fee Related CA2245398C (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002245398A CA2245398C (fr) 1998-08-21 1998-08-21 Clathrate d'isopropanol monohydrate d'azithromycine et methodes d'obtention
US09/373,549 US6245903B1 (en) 1998-08-21 1999-08-13 Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
DE69902212T DE69902212T2 (de) 1998-08-21 1999-08-20 Azithromycinmonohydrat-Isopropanol-Clathrate und Methoden zu deren Herstellung
EP99306612A EP0984020B1 (fr) 1998-08-21 1999-08-20 Clathrates d'azithromycine monohydratée et d'isopropanol ainsi que leur méthode de fabrication
AT99306612T ATE221078T1 (de) 1998-08-21 1999-08-20 Azithromycinmonohydrat-isopropanol-clathrate und methoden zu deren herstellung
US10/454,586 USRE39087E1 (en) 1998-08-21 2003-06-05 Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002245398A CA2245398C (fr) 1998-08-21 1998-08-21 Clathrate d'isopropanol monohydrate d'azithromycine et methodes d'obtention

Publications (3)

Publication Number Publication Date
CA2245398A1 CA2245398A1 (fr) 2000-02-21
CA2245398E true CA2245398E (fr) 2002-01-29
CA2245398C CA2245398C (fr) 2002-01-29

Family

ID=4162751

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002245398A Expired - Fee Related CA2245398C (fr) 1998-08-21 1998-08-21 Clathrate d'isopropanol monohydrate d'azithromycine et methodes d'obtention

Country Status (5)

Country Link
US (2) US6245903B1 (fr)
EP (1) EP0984020B1 (fr)
AT (1) ATE221078T1 (fr)
CA (1) CA2245398C (fr)
DE (1) DE69902212T2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
CA2245398C (fr) 1998-08-21 2002-01-29 Apotex Inc. Clathrate d'isopropanol monohydrate d'azithromycine et methodes d'obtention
SI20639A (sl) * 1998-11-30 2002-02-28 Teva Pharmaceutical Industries Ltd. Etanolat azitromicina, postopek za njegovo pripravo in njegovi farmacevtski sestavki
AU5820400A (en) * 1999-06-29 2001-01-31 Biochemie S.A. Macrolides
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
DE60026718T2 (de) 2000-07-25 2006-11-16 Laboratorio Silanes, S.A. De C.V. Einstufiges verfahren zur herstellung von 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle(11.2.11)hexadeca-1(2)-en-8-ona undeine neue form von 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin a
WO2002009640A2 (fr) * 2000-08-01 2002-02-07 Shiva Prasad Singh Élaboration d'azithromycine anhydre
JP2004506664A (ja) * 2000-08-23 2004-03-04 ウォックハート・リミテッド 無水アジトロマイシンの製造法
CN100341886C (zh) * 2000-11-27 2007-10-10 桑多斯股份公司 大环内酯类化合物的溶剂化物
HRP20030430B1 (hr) 2000-11-27 2011-11-30 Biochemie S.A. Makrolidni solvati
KR100491183B1 (ko) 2001-03-21 2005-05-25 한미약품 주식회사 아지트로마이신의 제조방법 및 이 방법에 사용되는9-데옥소-9에이-아자-9에이-호모에리트로마이신 에이의결정성 수화물
KR100431431B1 (ko) * 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
SI1390377T1 (sl) * 2001-05-22 2006-06-30 Pfizer Prod Inc Nova kristalna oblika azitromicina
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
ES2258142T3 (es) * 2001-05-22 2006-08-16 Pfizer Products Inc. Nueva forma cristalina.
PL371259A1 (pl) * 2001-12-21 2005-06-13 Pfizer Products Inc. Bezpośrednio sprasowywalne preparaty azytromycyny
NZ532063A (en) * 2001-12-21 2006-03-31 Pfizer Prod Inc Methods for wet granulating azithromycin
RU2283092C2 (ru) * 2002-02-01 2006-09-10 Пфайзер Продактс Инк. Сухие гранулированные композиции азитромицина
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
CA2422972A1 (fr) * 2003-03-21 2004-09-21 Apotex Inc. Isopropanolate d'azithromycine et methode de production connexe
EP1648472A2 (fr) * 2003-07-01 2006-04-26 Ranbaxy Laboratories, Ltd. Compositions orales stables de monohydrate d'azithromycine
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
ATE421882T1 (de) 2003-07-24 2009-02-15 Pliva Hrvatska D O O Schnellösliches azithromycin in einzeldosisform
CA2547597A1 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Compositions multiparticulaires a stabilite amelioree
MXPA06005913A (es) * 2003-12-04 2006-06-27 Pfizer Prod Inc Formas de dosificacion de multiparticulas de azitromicina por procedimientos basados en liquidos.
WO2005053652A1 (fr) 2003-12-04 2005-06-16 Pfizer Products Inc. Compositions medicamenteuses cristallines multiparticulaires contenant un poloxamere et un glyceride
WO2005053639A2 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Formes multiparticulaires a liberation controlee produites avec des optimiseurs de dissolution
KR100844628B1 (ko) * 2003-12-04 2008-07-07 화이자 프로덕츠 인크. 제약상 다입자의 제조 방법
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
ES2600577T3 (es) * 2003-12-04 2017-02-09 Bend Research, Inc. Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
WO2006011160A1 (fr) * 2004-06-28 2006-02-02 Alembic Limited Procede pour la preparation de clathrate d'isopropanol d'azithromycine monohydrate
US20090130154A1 (en) * 2004-08-26 2009-05-21 Bioderm Research Topical Delivery of Biological and Cosmetic Agents by Zeolites
US7683162B2 (en) * 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
CA2591744A1 (fr) * 2004-12-21 2006-06-29 Pfizer Products Inc. Suspension orales stables d'azithromycine sous forme non dihydrate
US7384922B2 (en) * 2005-05-04 2008-06-10 Enanta Pharmaceuticals, Inc. 6-11 bridged oxime erythromycin derivatives
US20090318375A1 (en) * 2005-06-08 2009-12-24 Hanmi Pharm Co., Ltd Crystalline Azithromycin L-Malate Monohydrate and Pharmaceutical Composition Containing Same
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
US20120058936A1 (en) 2009-03-13 2012-03-08 Assistance Publique - Hopitaux De Paris Compositions and methods for elimination of gram negative bacteria
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
CA2784494C (fr) 2009-12-18 2019-03-12 North-West University Composition comprenant une forme vitrifiee amorphe non cristalline de la roxithromycine
WO2013088274A1 (fr) 2011-12-14 2013-06-20 Wockhardt Limited Composition d'azithromycine amorphe anhydre dépourvue de dihydrate d'azithromycine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
JPS58157790A (ja) 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ７−デアザプリン誘導体およびその製造法
CA1202619A (fr) 1982-07-19 1986-04-01 Gene M. Bright Produits intermediaires pour la preparation de n-methyl 11-aza-10-desoxo-10-dihydroerythromycine a
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
WO1989000576A1 (fr) 1987-07-09 1989-01-26 Pfizer Inc. Dihydrate d'azithromycine
CN1093370A (zh) 1993-12-10 1994-10-12 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
US5808017A (en) * 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
DE69730138T2 (de) 1996-07-29 2005-03-03 Abbott Laboratories, Abbott Park Herstellung von kristallinen form ii von clarithromycin
SK142000A3 (en) * 1997-07-08 2000-06-12 Biochemie Sa Erythromycin a oxime solvates
CA2245398C (fr) 1998-08-21 2002-01-29 Apotex Inc. Clathrate d'isopropanol monohydrate d'azithromycine et methodes d'obtention
KR100377159B1 (ko) 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
SI20639A (sl) 1998-11-30 2002-02-28 Teva Pharmaceutical Industries Ltd. Etanolat azitromicina, postopek za njegovo pripravo in njegovi farmacevtski sestavki
AU5820400A (en) 1999-06-29 2001-01-31 Biochemie S.A. Macrolides
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina

Similar Documents

Publication Publication Date Title
CA2245398E (fr) Clathrate d'isopropanol monohydrate d'azithromycine et methodes d'obtention
CA2245398C (fr) Clathrate d'isopropanol monohydrate d'azithromycine et methodes d'obtention
RU2230748C2 (ru) Способ получения кларитромицина в виде кристаллов формы ii
US20260085065A1 (en) Crystalline form of sglt inhibitor
US4492688A (en) Antibacterial cyclic ethers of 9-deoxo-9a-aza-9a-homoerythromycin A and intermediates therefor
CA2067274C (fr) Solvates de dirithromycine et un procede pour les isoler du dirithromycine ii
SU1011051A3 (ru) Способ получени @ -гликозиловых производных антибиотиков из группы антрациклинов
NO146711B (no) Analogifremgangsmaate for fremstilling av oleandomycin- og erytromycinderivater
US4124755A (en) 11-Alkanoyl-4"-deoxy-4"-isonitrilo-oleandomycin derivatives
US5096905A (en) Basic cleavage products of elaiophylin and elaiophylin derivatives and use thereof
EP0087915B1 (fr) Oléandomycines et erythromycines semi-synthétiques
RU2802443C1 (ru) Промежуточное соединение, применяемое для синтеза ингибитора sglt, и способ получения ингибитора sglt с применением указанного промежуточного соединения
KR100452026B1 (ko) 6-메틸에리스로마이신 ａ의 제조방법
EP0132026B1 (fr) Ethers cycliques à activité antibactérielle, de 9-déoxy-9a-aza-9a-homoérythromycine et produits intermédiaires
KR100512776B1 (ko) 클라리스로마이신 결정형 ２형의 제조방법
MXPA04010587A (es) [2r-(2r*, 3s*, 4r*, 5r*, 8r*, 10r*, 11r*, 2s*, 3s*, 14r*)]- 13-[(2 6-d deoxi-3-c- metil- -l- ribo- hexopiranosil) oxi]-2-etil-3], 4, 10- trihidroxi-3, 5, 6, 8, 10, 12, 14-heptametil- 11-[[3, 4, 6-trideoxi- 3-(dimetilamino)- -d-xilo-5 hexopiranosil] o
CA1128506A (fr) Derives de 4"-erythromycine a semi-synthetiques
Hammann et al. Secondary metabolites by chemical screening-6 cleavage of elaiophylin and transformation into a spiroketal building block
WO2009090023A1 (fr) Forme cristalline i de l'ortataxel
MXPA04010586A (es) Un nuevo compuesto 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a cristalino anhidro y proceso para su fabricacion.
EA013082B1 (ru) Кристаллические формы макролидных соединений, обладающих противовоспалительной активностью
HK1131781A (en) Crystalline form i of ortataxel
JPH0149356B2 (fr)